Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.93

0.8 (5.29%)

07:23
01/11/19
01/11
07:23
01/11/19
07:23

Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo

Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.

  • 28

    Jan

HALO Halozyme
$15.93

0.8 (5.29%)

10/18/18
PIPR
10/18/18
INITIATION
Target $17
PIPR
Neutral
Halozyme assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.
11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.

TODAY'S FREE FLY STORIES

UNFI

United Natural Foods

$13.09

-2.32 (-15.06%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
United Natural Foods falls -15.1% »

United Natural Foods is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTE

Earthstone Energy

$5.28

-1.49 (-22.01%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Earthstone Energy falls -21.9% »

Earthstone Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$25.49

-7.885 (-23.63%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Signet Jewelers falls -23.6% »

Signet Jewelers is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$27.64

2.27 (8.95%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Skechers rises 9.2% »

Skechers is up 9.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSV

Carriage Services

$18.60

1.61 (9.48%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Carriage Services rises 9.6% »

Carriage Services is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNH

Senior Housing

$12.82

-0.07 (-0.54%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Options
Put buyers in Senior Housing Properties »

Put buyers in Senior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$0.00

(0.00%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Sears confirms ESL selected as winning bidder in bankruptcy auction »

Sears Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZM

Och-Ziff Capital

$12.51

1.27 (11.30%)

12:00
01/17/19
01/17
12:00
01/17/19
12:00
Hot Stocks
Och-Ziff Capital rises 11.1% »

Och-Ziff Capital is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$68.66

0.78 (1.15%)

, PLCE

Children's Place

$87.83

2.66 (3.12%)

11:57
01/17/19
01/17
11:57
01/17/19
11:57
Periodicals
Target revamps its baby line Cloud Island to include essential items, CNBC says »

With the demise of …

TGT

Target

$68.66

0.78 (1.15%)

PLCE

Children's Place

$87.83

2.66 (3.12%)

CRI

Carter's

$78.68

0.48 (0.61%)

GPS

Gap

$25.28

0.38 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

, AMPH

Amphastar

$21.90

0.1 (0.46%)

11:57
01/17/19
01/17
11:57
01/17/19
11:57
Recommendations
Emergent BioSolutions, Amphastar analyst commentary  »

Wells says naloxone news…

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

AMPH

Amphastar

$21.90

0.1 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

, AMPH

Amphastar

$21.91

0.11 (0.50%)

11:55
01/17/19
01/17
11:55
01/17/19
11:55
Hot Stocks
FDA commissioner describes efforts to support development of OTC naloxone »

FDA Commissioner Scott…

EBS

Emergent BioSolutions

$65.86

0.79 (1.21%)

AMPH

Amphastar

$21.91

0.11 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
01/17/19
01/17
11:55
01/17/19
11:55
General news
Treasury Option Action: a rash of put positioning »

Treasury Option Action: a…

NFLX

Netflix

$352.83

1.68 (0.48%)

11:54
01/17/19
01/17
11:54
01/17/19
11:54
On The Fly
Fly Intel: What to watch in Netflix earnings report »

Netflix (NFLX) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

11:45
01/17/19
01/17
11:45
01/17/19
11:45
General news
Treasury's 4- and 8-week bill auctions were solid and priced very well »

Treasury's 4- and…

WFC

Wells Fargo

$48.74

-0.19 (-0.39%)

11:40
01/17/19
01/17
11:40
01/17/19
11:40
Options
Size call butterfly spread in Wells Fargo after earnings »

Size call butterfly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

  • 12

    Apr

  • 28

    May

  • 13

    Jul

  • 12

    Oct

11:35
01/17/19
01/17
11:35
01/17/19
11:35
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:35
01/17/19
01/17
11:35
01/17/19
11:35
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

MRVL

Marvell

$16.43

-0.2 (-1.20%)

11:35
01/17/19
01/17
11:35
01/17/19
11:35
Options
Marvell put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

11:35
01/17/19
01/17
11:35
01/17/19
11:35
General news
Treasury announced an $81 B 3- and 6-month bill sale for Tuesday »

Treasury announced an $81…

MOFG

MidWestOne

$25.94

-0.03 (-0.12%)

11:33
01/17/19
01/17
11:33
01/17/19
11:33
Hot Stocks
MidWestOne raises quarterly dividend 3.8% to 20.25c per share »

MidWestOne Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$102.10

-0.38 (-0.37%)

, PYPL

PayPal

$90.34

-0.18 (-0.20%)

11:29
01/17/19
01/17
11:29
01/17/19
11:29
Earnings
Fly Intel: What to watch in credit card space earnings reports »

American Express (AXP),…

JPM

JPMorgan

$102.10

-0.38 (-0.37%)

PYPL

PayPal

$90.34

-0.18 (-0.20%)

MA

MasterCard

$198.34

0.56 (0.28%)

V

Visa

$137.01

-0.31 (-0.23%)

AXP

American Express

$99.38

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 25

    Feb

  • 26

    Feb

  • 03

    Mar

  • 28

    May

FB

Facebook

$148.78

1.3 (0.88%)

11:26
01/17/19
01/17
11:26
01/17/19
11:26
Periodicals
Facebook manager quits after being 'harassed' over views, CNBC reports »

Sophie Alpert, a Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

USO

United States Oil Fund

$10.77

-0.275 (-2.49%)

11:20
01/17/19
01/17
11:20
01/17/19
11:20
Options
Size straddle crossed firm-to-firm tied to stock in US Oil ETF »

Size straddle crossed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/19
01/17
11:17
01/17/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/19
01/17
11:16
01/17/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.